📰 GPCR Weekly News, September 4 to 10, 2023
Good day readers! Welcome to our latest GPCR updates.
This week's highlights:
Dr. Yamina Berchiche, Founder and Director of Dr. GPCR, was featured as Superluminal Medicines Launches to Drug Protein Conformations in a Flash.
Our partner, Domain Therapeutics, will attend the SACHS 23rd annual biotech event in Europe.
Dr. Gregory Tall and team's study on GPR114/ADGRG5, activated by tethered-peptide-agonist, a cleaved adhesion GPCR.
Dr. Christopher Langmead and colleagues' work on the 5-HT2C receptor as a therapeutic target for substance use disorders.
Save these dates:
September 22: Join us for the Dr. GPCR Symposium on ''GPCRs as Therapeutic Modalities' Share your project with a 1-minute abstract video with this form.
November 2 - 4: The GPCR Retreat is approaching and we are thrilled to be sponsors! Submit poster abstracts here; short talks will be selected from Abstracts. Abstract submissions close on October 2, and final registration ends on September 21.
Subscribe to the Dr. GPCR Newsletter for more insights!
Now, explore the Classified GPCR News from September 4th to 10th, 2023.
Adhesion GPCRs
GPCR Activation and Signaling
GPCR Binders, Drugs, and more
GPCRs in Neuroscience
GPCRs in Oncology and Immunology
Methods & Updates in GPCR Research
Reviews, GPCRs, and more
Structural and Molecular Insights into GPCR Function
Industry News
Superluminal Medicines Launches to Drug Protein Conformations in a Flash
Confo Therapeutics Appoints Stephen Dowd As Chief Business Officer
Septerna Announces Novel GPCR-targeted Program Acquired by Vertex
Call for GPCR Papers
GPCR Events, Meetings, and Webinars
February 3 - 7, 2024 | SLAS2024 International Conference and Exhibition
March 23 - 24, 2024 | Ligand Recognition and Molecular Gating Seminar
March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference
May 27 - 29, 2024 | SLAS Europe 2024 Conference and Exhibition